Megan Anne Harrison
Research Subjects
Megan Anne Harrison has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Elizabeth S. Sandberg
Department of Pediatrics, Division of Endocrinology, C.S. Mott Children's Hospital, University of Michigan, Ann Arbor, Michigan, USA
1 shared publication - Kristen N. Lee
Department of Internal Medicine, University of Michigan , Ann Arbor, MI 48109
1 shared publication - Mark Dulchavsky
Howard Hughes Medical Institute, University of Michigan, Ann Arbor, USA
1 shared publication - Rebecca Patterson1 shared publication
- Sruchika Sabu
Affiliation Department of Pediatrics, Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States of America
1 shared publication
Latest Publications
- Open Access
- 5 July 2026
- Published by Elsevier in SSRN Electronic Journal
Hyperthyroidism-Associated Metabolic Decompensation in Maple Syrup Urine Disease
BackgroundMaple syrup urine disease (MSUD) is an inherited disorder of branched-chain amino acid metabolism in which metabolic decompensation is commonly triggered by catabolic stress. Hyperthyroidism has rarely been reported as a precipitant of hyperleucinosis in patients with MSUD, with only a single prior case identified in the literature.Case PresentationA 21-year-old man with classic MSUD and previously stable metabolic control developed persistent hyperleucinosis despite adherence to typical sick-day management and without an easily identifiable trigger. Following hospital admission for refractory hyperleucinosis, evaluation revealed thyrotoxicosis with suppressed thyroid-stimulating hormone and elevated free thyroxine. Further investigation demonstrated positive thyroid peroxidase antibodies and findings consistent with Hashitoxicosis secondary to Hashimoto’s thyroiditis. Because standard therapies for thyroiditis-associated thyrotoxicosis posed challenges in the setting of MSUD, treatment was initiated with cholestyramine and propranolol. Following treatment of thyrotoxicosis and continued metabolic support, plasma leucine concentrations declined rapidly and normalized after discharge. The patient subsequently transitioned to hypothyroidism and required levothyroxine replacement therapy.ConclusionThis case highlights thyrotoxicosis due to Hashimoto’s thyroiditis as a potentially underrecognized trigger of metabolic decompensation in MSUD and supports consideration of thyroid disease in patients with unexplained metabolic instability.
- 5 July 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessHyperthyroidism-Associated Metabolic Decompensation in Maple Syrup Urine Disease
BackgroundMaple syrup urine disease (MSUD) is an inherited disorder of branched-chain amino acid metabolism in which metabolic decompensation is commonly triggered by catabolic stress. Hyperthyroidism has rarely been reported as a precipitant of hyperleucinosis in patients with MSUD, with only a single prior case identified in the literature.Case PresentationA 21-year-old man with classic MSUD and previously stable metabolic control developed persistent hyperleucinosis despite adherence to typical sick-day management and without an easily identifiable trigger. Following hospital admission for refractory hyperleucinosis, evaluation revealed thyrotoxicosis with suppressed thyroid-stimulating hormone and elevated free thyroxine. Further investigation demonstrated positive thyroid peroxidase antibodies and findings consistent with Hashitoxicosis secondary to Hashimoto’s thyroiditis. Because standard therapies for thyroiditis-associated thyrotoxicosis posed challenges in the setting of MSUD, treatment was initiated with cholestyramine and propranolol. Following treatment of thyrotoxicosis and continued metabolic support, plasma leucine concentrations declined rapidly and normalized after discharge. The patient subsequently transitioned to hypothyroidism and required levothyroxine replacement therapy.ConclusionThis case highlights thyrotoxicosis due to Hashimoto’s thyroiditis as a potentially underrecognized trigger of metabolic decompensation in MSUD and supports consideration of thyroid disease in patients with unexplained metabolic instability.